February 14, 1996JAMA

FDA Gives Calcium Channel Blockers Clean Bill of Health but Warns of Short-Acting Nifedipine Hazards

View Full Paper

Ask AI

Bookmark

Population

Patients with hypertension and unstable angina

Design

Editorial

Authors

CMCharles MarwickAmerican Medical Association

Discussion

Member takes

Implication

An FDA advisory committee affirmed the general safety of calcium channel blockers for hypertension but warned of increased myocardial infarction risk associated with short-acting nifedipine.

Structured PICO

Population

Patients with hypertension and unstable angina

Intervention

Calcium channel blockers (specifically short-acting nifedipine)

Outcome

Myocardial infarction risksafety

An FDA advisory committee affirmed the general safety of calcium channel blockers for hypertension but warned of increased myocardial infarction risk associated with short-acting nifedipine.

Cite This Study

Charles Marwick (1996) studied this question.

synapsesocial.com/papers/6a8fb9b0b2cf76216e4a3556 https://doi.org/10.1001/jama.1996.03530300007004

View Full Paper

Ask AI

Bookmark

Implication

An FDA advisory committee affirmed the general safety of calcium channel blockers for hypertension but warned of increased myocardial infarction risk associated with short-acting nifedipine.

FDA Gives Calcium Channel Blockers Clean Bill of Health but Warns of Short-Acting Nifedipine Hazards

Discussion

Member takes

Implication

Structured PICO

Cite This Study

FDA Gives Calcium Channel Blockers Clean Bill of Health but Warns of Short-Acting Nifedipine Hazards

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider